Xinzhou Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinzhou Zhang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Hua Xiao
Department of Nephrology, The Affiliated Shunde Hospital of Jinan University, Guangdong, China
3 shared publicationsZhimei Peng
Department of Nephrology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital
3 shared publicationsDi Wu
Department of Nephrology, The First Affiliated Hospital of Shenzhen University (Shenzhen Second People’s Hospital), Shenzhen, China
1 shared publication- Guo-Bao Hong
Department of Nephrology, The Affiliated Shunde Hospital of Jinan University, Foshan, Guangdong, China
1 shared publication Hanyong Liu
Shenzhen Key Laboratory of Kidney Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China
1 shared publicationHaofei Hu
Department of Nephrology, The First Affiliated Hospital of Shenzhen University (Shenzhen Second People’s Hospital), Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1934995
Case Report: Clinical insights into IgG4-related nephropathy with overlapping syndrome: a review of two cases
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by small-vessel inflammation, whereas immunoglobulin G4-related disease (IgG4-RD) is typified by fibrosis, dense lymphoplasmacytic infiltration, and the presence of IgG4-positive plasma cells. The overlapping clinical, serological, radiological, and histopathological features between these distinct entities pose significant diagnostic challenges, frequently culminating in poor prognoses for elderly patients with concurrent diabetes mellitus. Herein, we report two cases of IgG4-related tubulointerstitial nephritis (IgG4-TIN). Case 1 describes a 77-year-old diabetic male exhibiting concurrent features of proteinase 3 (PR3)-positive AAV (including pulmonary lesions, hematuria, and rapid renal function decline) and IgG4-TIN, further complicated by chronic heart failure and peripheral neuropathy. The patient demonstrated a suboptimal therapeutic response to standard regimens of corticosteroids and monoclonal antibodies. Case 2 involves a patient presenting with mass-forming retroperitoneal fibrosis that led to obstructive uropathy and acute kidney injury. Of particular clinical note, Case 1 was complicated by an inadvertent lumbar artery puncture during renal biopsy, which precipitated hemorrhagic shock requiring urgent transcatheter arterial embolization. This comparative analysis elucidates the diagnostic and therapeutic complexities of IgG4-nephropathy in elderly, comorbid populations, while also underscoring the critical management of rare, life-threatening procedural complications.
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1934995
Open AccessCase Report: Clinical insights into IgG4-related nephropathy with overlapping syndrome: a review of two cases
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by small-vessel inflammation, whereas immunoglobulin G4-related disease (IgG4-RD) is typified by fibrosis, dense lymphoplasmacytic infiltration, and the presence of IgG4-positive plasma cells. The overlapping clinical, serological, radiological, and histopathological features between these distinct entities pose significant diagnostic challenges, frequently culminating in poor prognoses for elderly patients with concurrent diabetes mellitus. Herein, we report two cases of IgG4-related tubulointerstitial nephritis (IgG4-TIN). Case 1 describes a 77-year-old diabetic male exhibiting concurrent features of proteinase 3 (PR3)-positive AAV (including pulmonary lesions, hematuria, and rapid renal function decline) and IgG4-TIN, further complicated by chronic heart failure and peripheral neuropathy. The patient demonstrated a suboptimal therapeutic response to standard regimens of corticosteroids and monoclonal antibodies. Case 2 involves a patient presenting with mass-forming retroperitoneal fibrosis that led to obstructive uropathy and acute kidney injury. Of particular clinical note, Case 1 was complicated by an inadvertent lumbar artery puncture during renal biopsy, which precipitated hemorrhagic shock requiring urgent transcatheter arterial embolization. This comparative analysis elucidates the diagnostic and therapeutic complexities of IgG4-nephropathy in elderly, comorbid populations, while also underscoring the critical management of rare, life-threatening procedural complications.
- Open Access
- 7 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Incidence and pathological features of IgA nephropathy before and during the COVID-19 pandemic
IgA nephropathy (IgAN) imposes a substantial burden of illness and death. However, a systematic evaluation of the impact of the COVID-19 pandemic on the incidence and pathology of IgAN has yet to be performed. In this study, we analyzed kidney biopsy results from two medical institutions, covering the timeframe from January 2016 to May 2023. We conducted statistical analyses on various glomerular diseases according to their corresponding pathological diagnoses. Our objective was to compare the incidence of different glomerular diseases before and during the COVID-19 pandemic. The study focused on variations in the incidence of IgAN, and collected clinical and pathological data to assess pathological changes using the Oxford Classification (MEST-C). The findings revealed a significant increase in the incidence of IgAN during the COVID-19 pandemic, from 39.9% prior to the pandemic to 46.3% during it, representing a net increase of 6.4% (P < 0.001). Although clinical manifestations and laboratory indicators of disease activity in IgAN patients remained consistent over both periods, observable changes occurred in pathological features. Specifically, the proportions of M1 and E1 lesions according to the Oxford classification significantly increased during the pandemic, with odds ratios of 11.764 (95% CI 5.583–24.789, P < 0.001) and 1.718 (95% CI 1.114–2.649, P = 0.014), respectively. Our results indicate that the incidence of IgAN has risen during the COVID-19 pandemic, along with exacerbated renal damage and elevated proportions of M1 and E1 in the Oxford classification.
- 7 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessIncidence and pathological features of IgA nephropathy before and during the COVID-19 pandemic
IgA nephropathy (IgAN) imposes a substantial burden of illness and death. However, a systematic evaluation of the impact of the COVID-19 pandemic on the incidence and pathology of IgAN has yet to be performed. In this study, we analyzed kidney biopsy results from two medical institutions, covering the timeframe from January 2016 to May 2023. We conducted statistical analyses on various glomerular diseases according to their corresponding pathological diagnoses. Our objective was to compare the incidence of different glomerular diseases before and during the COVID-19 pandemic. The study focused on variations in the incidence of IgAN, and collected clinical and pathological data to assess pathological changes using the Oxford Classification (MEST-C). The findings revealed a significant increase in the incidence of IgAN during the COVID-19 pandemic, from 39.9% prior to the pandemic to 46.3% during it, representing a net increase of 6.4% (P < 0.001). Although clinical manifestations and laboratory indicators of disease activity in IgAN patients remained consistent over both periods, observable changes occurred in pathological features. Specifically, the proportions of M1 and E1 lesions according to the Oxford classification significantly increased during the pandemic, with odds ratios of 11.764 (95% CI 5.583–24.789, P < 0.001) and 1.718 (95% CI 1.114–2.649, P = 0.014), respectively. Our results indicate that the incidence of IgAN has risen during the COVID-19 pandemic, along with exacerbated renal damage and elevated proportions of M1 and E1 in the Oxford classification.
- 15 November 2024
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (3) , 999-1008
Association between the use of loop diuretics and prognosis in critically ill patients with acute kidney injury: a retrospective propensity score-matched cohort study
Background The role of loop diuretics in patients with acute kidney injury (AKI) is controversial. This study examined the association between the use of loop diuretics and prognosis in critically ill patients with AKI. Methods This study used data from the medical information mart for the intensive care IV database. Adult critically ill patients with AKI were included in the analysis. Patients were partitioned into two groups based on their use of loop diuretics in the ICU, and potentially confounding variables between the two groups were balanced using propensity score matching (PSM). We used time-dependent Cox proportional hazards regression, logistic regression, and Hodges–Lehman estimator to assess the impact of loop diuretics on all-cause mortality, renal replacement therapy (RRT) use, and the length of hospital stay, respectively. Results This study included a cohort of 19,671 patients. After PSM, both groups consisted of 6200 patients. The use of loop diuretics was associated with a lower risk of in-hospital mortality (HR, 0.672; 95% CI 0.597–0.757; P < 0.001), lower in-ICU mortality (HR, 0.375; 95% CI 0.315–0.446; P < 0.001), and lower odds of in-hospital RRT (OR, 0.472; 95% CI 0.400–0.555; P < 0.001). A sensitivity analysis using the original cohort (HR, 0.624; 95% CI 0.561–0.693; P < 0.001) and weighted cohort (HR, 0.654; 95% CI 0.582–0.736; P < 0.001) also demonstrated lower in-hospital all-cause mortality. Conclusions The use of loop diuretics is associated with a substantial reduction in mortality among critically ill patients with AKI.
- 15 November 2024
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (3) , 999-1008
Association between the use of loop diuretics and prognosis in critically ill patients with acute kidney injury: a retrospective propensity score-matched cohort study
Background The role of loop diuretics in patients with acute kidney injury (AKI) is controversial. This study examined the association between the use of loop diuretics and prognosis in critically ill patients with AKI. Methods This study used data from the medical information mart for the intensive care IV database. Adult critically ill patients with AKI were included in the analysis. Patients were partitioned into two groups based on their use of loop diuretics in the ICU, and potentially confounding variables between the two groups were balanced using propensity score matching (PSM). We used time-dependent Cox proportional hazards regression, logistic regression, and Hodges–Lehman estimator to assess the impact of loop diuretics on all-cause mortality, renal replacement therapy (RRT) use, and the length of hospital stay, respectively. Results This study included a cohort of 19,671 patients. After PSM, both groups consisted of 6200 patients. The use of loop diuretics was associated with a lower risk of in-hospital mortality (HR, 0.672; 95% CI 0.597–0.757; P < 0.001), lower in-ICU mortality (HR, 0.375; 95% CI 0.315–0.446; P < 0.001), and lower odds of in-hospital RRT (OR, 0.472; 95% CI 0.400–0.555; P < 0.001). A sensitivity analysis using the original cohort (HR, 0.624; 95% CI 0.561–0.693; P < 0.001) and weighted cohort (HR, 0.654; 95% CI 0.582–0.736; P < 0.001) also demonstrated lower in-hospital all-cause mortality. Conclusions The use of loop diuretics is associated with a substantial reduction in mortality among critically ill patients with AKI.
- Open Access
Spotlight on macrophage pyroptosis: A bibliometric and visual analysis from 2001 to 2023
- Open Access
- 9 September 2023
- Published by Elsevier in Cellular Signalling
- Vol. 111, 110883
Downregulation of ARNTL in renal tubules of diabetic db/db mice reduces kidney injury by inhibiting ferroptosis
- 9 September 2023
- Published by Elsevier in Cellular Signalling
- Vol. 111, 110883
Open AccessDownregulation of ARNTL in renal tubules of diabetic db/db mice reduces kidney injury by inhibiting ferroptosis
- Open Access
- 4 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 166, 115422
New insights into the mechanisms of diabetic kidney disease: Role of circadian rhythm and Bmal1
- 4 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 166, 115422
Open AccessNew insights into the mechanisms of diabetic kidney disease: Role of circadian rhythm and Bmal1